And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our own agenda is somewhat promising. We hope to hang with one or more short people, catch up on our reading, and touch base with a like-minded conspirator from our past. And what about you? Spring is closing in quickly, so this may be a good time to get a head start on cleaning out your castle or taking in the great outdoors. You could count your blessings that you got your college degree the old-fashioned way — you earned it. Or maybe simply make time for someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

A debate over the use of list prices to gauge the rising cost of medicines broke out in the Health Affairs blog. Robert DuBois of the National Pharmaceutical Council criticized a recent paper by arguing that “the use of list price leads to misleading results” because these do not reflect rebates paid by drug makers to win favorable insurance coverage. But the authors of that paper countered that it would be “problematic” to withhold research based on list prices because uninsured and underinsured patients are exposed to list prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This quote from Purdue bemuses me – “will not profit from nalmefene HCI.” And so they will seque to being a ‘not for profit’ company? Am I alone in find this … bemusing? (Or odd / confusing, if you prefer …)